Enzyme News and Research

RSS

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

A new study compares antibody levels in newborns born from mothers vaccinated against COVID-19 and to maternal infection with SARS-CoV-2.

9 Feb 2022

How SARS-CoV-2 infection progresses throughout the respiratory system

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

9 Feb 2022

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Researchers investigated the dynamics and longevity of neutralizing antibody response up to 480 days after the onset of infection in convalescent COVID-19 patients.

9 Feb 2022

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

In a new study, researchers revealed that the nucleotide-binding oligomerization domain-like receptors or NOD-like receptors family pyrin domain containing 3 (NLRP3) inflammasome is activated by the exosomes from plasma in COVID-19.

9 Feb 2022

Researchers identify a bivalent histone-mark switch essential for angiogenesis

Defying conventional epigenomic wisdom, the non-conventional polycomb (PRC)1 variant paradoxically overwhelms the conventional PRC-mediated gene silencing in activated endothelial cells.

8 Feb 2022

Efficacy of MVA-CoV2-S vaccination to prevent SARS-CoV-2 cerebral infection and associated damage

Researchers demonstrated that an MVA vector expressing the SARS-CoV-2 spike protein was 100% effective in preventing neuroinvasion and brain damage by SARS-CoV-2 in transgenic mice.

8 Feb 2022

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

In a recent study published in the journal ACS Applied Bio Materials, researchers demonstrated the inhibitory potential of curcumin-encapsulated polysaccharide nanoparticles (CUR−PS-NPs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (CoV2-SP)-stimulated cytokine storm in lung and liver epithelial cells.

8 Feb 2022

Investigating taraxerol as a protease inhibitor against SARS-CoV-2

In a recent study posted to the Research Square preprint* server, a team of researchers investigated the toxicity and absorption, distribution, metabolism, and excretion (ADME) characteristics of a potent herbal drug, taraxerol, in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The paper is under consideration for publication in the Structural Chemistry journal.

7 Feb 2022

Study shows chronic alcohol consumption as a potential risk factor for SARS-CoV-2-infection

In a study posted to the bioRxiv* preprint server, a team of researchers from Germany studied the expression data of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-relevant genes such as angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), and the G-protein coupled receptor Mas in an alcohol-exposed rodent model infected with SARS-CoV-2.

7 Feb 2022

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Researchers validate a quick, highly efficient, and automated assay to detect neutralizing antibodies against SARS-CoV-2.

7 Feb 2022

Investigating the immunology of COVID-19 infected children

Researchers published a new study that focused on the key principles of developmental immunology associated with immunobiology and the clinical impacts of COVID-19 infections in children and adults.

7 Feb 2022

Evolutionary history of ACE2 binding across a diverse range of sarbecoviruses and ACE2 orthologs

Researchers have been investigating sarbecovirus lineages and the ability of those lineages to evolve the ability to bind ACE2.

7 Feb 2022

Study links COVID-19 inflammatory manifestations in brain lysates to Alzheimer’s Disease markers

In a new study, researchers investigated a link between the body’s inflammatory response to SARS-CoV-2 infection within the neuropathological pathways and tau hyperphosphorylation.

7 Feb 2022

Cerebrovascular impairment persists months after severe acute COVID-19, UK study

Researchers in the United Kingdom have conducted an observational cohort study on hospitalized patients and have found that the degree of severity of acute coronavirus disease 2019 (COVID-19) predicts the occurrence of chronic cerebrovascular impairment. The study further suggests that the levels of cerebrovascular impairment are associated with worse cognitive, mental, and physical well-being.

7 Feb 2022

Enzyme News and Research

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

How SARS-CoV-2 infection progresses throughout the respiratory system

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

Researchers identify a bivalent histone-mark switch essential for angiogenesis

Efficacy of MVA-CoV2-S vaccination to prevent SARS-CoV-2 cerebral infection and associated damage

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

Investigating taraxerol as a protease inhibitor against SARS-CoV-2

Study shows chronic alcohol consumption as a potential risk factor for SARS-CoV-2-infection

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Investigating the immunology of COVID-19 infected children

Evolutionary history of ACE2 binding across a diverse range of sarbecoviruses and ACE2 orthologs

Study links COVID-19 inflammatory manifestations in brain lysates to Alzheimer’s Disease markers

Cerebrovascular impairment persists months after severe acute COVID-19, UK study

Women, smokers and drinkers more likely to develop taste or smell disorders from COVID

Researchers find a way to interfere with the energy pathway that promotes liver cancer spread

Memory B cells found to potently neutralize SARS-CoV-2 Omicron variant

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo